The first approved norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD demonstrated symptom improvements as early as week 1 in phase 3 trials.
Researchers found greater reductions in body mass index and participant-reported hunger scores with setmelanotide than with placebo, although adverse and serious adverse events were more frequent in the setmelanotide group; only one serious adverse event was considered treatment-related.
Voters will decide whether to expand lawmakers' authority to tax currently exempt healthcare goods and services, raising concerns about patient costs and healthcare access.
A nationwide birth cohort found lower odds of short sleep at 1 year among infants breastfed during the first 6 months of life, regardless of formula supplementation.
From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.